Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BloombergTV Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::35002876.png) Bloomberg TV [@BloombergTV](/creator/twitter/BloombergTV) on x 856K followers
Created: 2025-06-02 15:34:43 UTC

Bristol-Myers Squibb will pay BioNTech as much as $XXXX billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors. 

 Damian Garde reports

![](https://pbs.twimg.com/amplify_video_thumb/1929562194020024320/img/3IldRPyK6KKreSc6.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1929562331303854520/c:line.svg)

[Post Link](https://x.com/BloombergTV/status/1929562331303854520)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

BloombergTV Avatar Bloomberg TV @BloombergTV on x 856K followers Created: 2025-06-02 15:34:43 UTC

Bristol-Myers Squibb will pay BioNTech as much as $XXXX billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.

Damian Garde reports

XXXXX engagements

Engagements Line Chart

Post Link

post/tweet::1929562331303854520
/post/tweet::1929562331303854520